278 related articles for article (PubMed ID: 37833861)
21. Circulating levels of tumor necrosis factor soluble receptors in systemic lupus erythematosus are significantly higher than in other rheumatic diseases and correlate with disease activity.
Gabay C; Cakir N; Moral F; Roux-Lombard P; Meyer O; Dayer JM; Vischer T; Yazici H; Guerne PA
J Rheumatol; 1997 Feb; 24(2):303-8. PubMed ID: 9034987
[TBL] [Abstract][Full Text] [Related]
22. Elevated serum interleukin-34 level in juvenile systemic lupus erythematosus and disease activity.
El-Banna HS; El Khouly RM; Gado SE
Clin Rheumatol; 2020 May; 39(5):1627-1632. PubMed ID: 31907692
[TBL] [Abstract][Full Text] [Related]
23. Elevated serum interleukin-15 levels in systemic lupus erythematosus.
Park YB; Kim DS; Lee WK; Suh CH; Lee SK
Yonsei Med J; 1999 Aug; 40(4):343-8. PubMed ID: 10487137
[TBL] [Abstract][Full Text] [Related]
24. Tumour necrosis factor alpha and its soluble receptors parallel clinical disease and autoimmune activity in systemic lupus erythematosus.
Studnicka-Benke A; Steiner G; Petera P; Smolen JS
Br J Rheumatol; 1996 Nov; 35(11):1067-74. PubMed ID: 8948291
[TBL] [Abstract][Full Text] [Related]
25. [Proinflammatory cytokines in inactive lupus erythematosus patients].
Lesiak A; Sysa-Jedrzejowska A; Narbutt J; Lukamowicz J; Robak E; Wozniacka A
Przegl Lek; 2005; 62(9):838-42. PubMed ID: 16541713
[TBL] [Abstract][Full Text] [Related]
26. Effect of proinflammatory cytokines (IL-6, TNF-α, and IL-1β) on clinical manifestations in Indian SLE patients.
Umare V; Pradhan V; Nadkar M; Rajadhyaksha A; Patwardhan M; Ghosh KK; Nadkarni AH
Mediators Inflamm; 2014; 2014():385297. PubMed ID: 25548434
[TBL] [Abstract][Full Text] [Related]
27. Serum neopterin, tumor necrosis factor-alpha and soluble tumor necrosis factor receptor II (p75) levels and disease activity in Egyptian female patients with systemic lupus erythematosus.
Mahmoud RA; El-Gendi HI; Ahmed HH
Clin Biochem; 2005 Feb; 38(2):134-41. PubMed ID: 15642275
[TBL] [Abstract][Full Text] [Related]
28. Efficacy analysis of hydroxychloroquine therapy in systemic lupus erythematosus: a study on disease activity and immunological biomarkers.
Monzavi SM; Alirezaei A; Shariati-Sarabi Z; Tavakol Afshari J; Mahmoudi M; Dormanesh B; Jahandoost F; Khoshdel AR; Etemad Rezaie A
Inflammopharmacology; 2018 Oct; 26(5):1175-1182. PubMed ID: 29987550
[TBL] [Abstract][Full Text] [Related]
29. Higher CD4
Zhu L; Song G; Chen X; Zhang Y; Cui Y; Qiao J; Huang X; Li X; Liu X; Zeng X; Li Y; Wang L; Li B
Sci Rep; 2023 Jul; 13(1):10702. PubMed ID: 37400575
[TBL] [Abstract][Full Text] [Related]
30. Interleukin 1, interleukin 6, interleukin 10, and tumor necrosis factor α in active and quiescent systemic lupus erythematosus.
Cigni A; Pileri PV; Faedda R; Gallo P; Sini A; Satta AE; Marras R; Carta E; Argiolas D; Rum I; Masala A
J Investig Med; 2014 Jun; 62(5):825-9. PubMed ID: 24987977
[TBL] [Abstract][Full Text] [Related]
31. Tumor necrosis factor‑α in systemic lupus erythematosus: Structure, function and therapeutic implications (Review).
Ghorbaninezhad F; Leone P; Alemohammad H; Najafzadeh B; Nourbakhsh NS; Prete M; Malerba E; Saeedi H; Tabrizi NJ; Racanelli V; Baradaran B
Int J Mol Med; 2022 Apr; 49(4):. PubMed ID: 35137914
[TBL] [Abstract][Full Text] [Related]
32. Association of interleukin 33 gene polymorphisms with susceptibility and regulation of inflammatory mediators in Systemic lupus erythematosus patients.
Bagheri-Hosseinabadi Z; Mirzaei MR; Aliakbari M; Abbasifard M
Clin Rheumatol; 2023 Aug; 42(8):2187-2197. PubMed ID: 37067648
[TBL] [Abstract][Full Text] [Related]
33. Cytokine panel and histopathological aspects in the systemic lupus erythematosus.
Avrămescu C; Biciuşcă V; Dăianu T; Turculeanu A; Bălăşoiu M; Popescu SN; Ionete O; Simionescu C
Rom J Morphol Embryol; 2010; 51(4):633-40. PubMed ID: 21103619
[TBL] [Abstract][Full Text] [Related]
34. Profiles of cytokines (TNF alpha and IL-6) and acute phase proteins (CRP and alpha 1AG) related to the disease course in patients with systemic lupus erythematosus.
Meijer C; Huysen V; Smeenk RT; Swaak AJ
Lupus; 1993 Dec; 2(6):359-65. PubMed ID: 7511020
[TBL] [Abstract][Full Text] [Related]
35. Monoclonal anti-double-stranded DNA autoantibody stimulates the expression and release of IL-1beta, IL-6, IL-8, IL-10 and TNF-alpha from normal human mononuclear cells involving in the lupus pathogenesis.
Sun KH; Yu CL; Tang SJ; Sun GH
Immunology; 2000 Mar; 99(3):352-60. PubMed ID: 10712664
[TBL] [Abstract][Full Text] [Related]
36. Th1/Th2 cytokine profile in childhood-onset systemic lupus erythematosus.
Postal M; Peliçari KO; Sinicato NA; Marini R; Costallat LT; Appenzeller S
Cytokine; 2013 Mar; 61(3):785-91. PubMed ID: 23332615
[TBL] [Abstract][Full Text] [Related]
37. Gene expression of cytokines (TNF-α, IFN-γ), serum profiles of IL-17 and IL-23 in paediatric systemic lupus erythematosus.
Rana A; Minz RW; Aggarwal R; Anand S; Pasricha N; Singh S
Lupus; 2012 Sep; 21(10):1105-12. PubMed ID: 22759859
[TBL] [Abstract][Full Text] [Related]
38. Analysis of Serum Interleukin (IL)-1β and IL-18 in Systemic Lupus Erythematosus.
Mende R; Vincent FB; Kandane-Rathnayake R; Koelmeyer R; Lin E; Chang J; Hoi AY; Morand EF; Harris J; Lang T
Front Immunol; 2018; 9():1250. PubMed ID: 29930551
[TBL] [Abstract][Full Text] [Related]
39. Altered expression of miR-125a and dysregulated cytokines in systemic lupus erythematosus: Unveiling diagnostic and prognostic markers.
Alsbihawi TQ; Zare Ebrahimabad M; Seyedhosseini FS; Davoodi H; Abdolahi N; Nazari A; Mohammadi S; Yazdani Y
World J Exp Med; 2023 Dec; 13(5):102-114. PubMed ID: 38173550
[TBL] [Abstract][Full Text] [Related]
40. Macrophage colony-stimulating factor could evaluate both disease activity and renal involvement in systemic lupus erythematosus.
Wang R; Zhao H; Liu Y; Li Y; Cai J
Ann Palliat Med; 2021 Feb; 10(2):2098-2107. PubMed ID: 33549023
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
